CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D013651: Taste Disorders NIH

(Synonyms: Taste Disorders)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (0)


Name (Synonyms) Correlation

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Prevalence and Clinical Evolution of Olfactory and Taste Disorders in Patients Infected by SARS-CoV-2

A novel coronavirus SARS-CoV-2 HAS arose in 2019 in Wuhan, China. Beside the classical semiology of this infection, numerous patients described olfactory and teste disorders. These symptoms are not described in this coronavirus, neurotropism of coronaviridae has been documented before. The aim of the study is to evaluate prevalence of anosmia and dysgeusia (olfactory and taste disorders) in coronavirus diagnosed patients and compare with different clinical conditions. The second endpoint is to evaluate the duration of these symptoms in order to better understand the semiology of this infection.

NCT04361565 COVID-19 by SARS-CoV-2 Infection
MeSH:Taste Disorders

Primary Outcomes

Description: Prevalence for anosmia in the COVID-19 + patients

Measure: Anosmia

Time: 45 days

Description: Prevalence for ageusia in the COVID-19 + patients

Measure: Ageusia

Time: 45 days

Description: Duration measured in days

Measure: Duration of the loss of anosmia ageusia

Time: 45 days


HPO Nodes